Pioglitazone Induced Reversible Pancytopenia

Abstract

Pioglitazone is used to improve insulin sensitivity in type 2 diabetes. This group of drugs is usually well tolerated; however, their use may be associated with several adverse effects including edema, weight gain, macular edema and heart failure. Herein we report a patient who developed pancytopenia on the 7th day of oral pioglitazone treatment for the control of diabetes mellitus and fully recovered 6 days after the cessation of this drug. To the best of our knowledge this is the first reported case of pancytopenia induced by pioglitazone therapy.

Key words

pioglitazone - diabetes mellitus type 2 - pancytopenia

References

• 1 Rizos CV, Elisaf MS, Mikhailidis DP. et al . How safe is the use of thiazolidinediones in clinical practice?.  Expert Opin Drug Saf. 2009;  8 ((1)) 15-32
• 2 Digman C, Klein AK, Pittas AG. Leukopenia and thrombocytopenia caused by thiazolidinediones.  Ann Intern Med. 2005 20;  143 ((6)) 465-466
• 3 Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials.  Lancet. 2007;  370 1129-1136
• 4 Berria R, Glass L, Mahankali A. et al . Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus.  Clin Pharmacol Ther. 2007;  82 ((3)) 275-281
• 5 Maaravi Y, Stessman J. Mild, reversible pancytopenia induced by rosiglitazone.  Diabetes Care. 2005;  28 ((6)) 1536
• 6 Akbiyik F, Ray DM, Gettings KF. et al . Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes.  Blood. 2004;  104 1361-1368

Correspondence